Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Bristol/Gilead joint venture targets 2005 filing for fixed-dose HIV combo. A new brand name for the fixed-dose combination of Bristol’s Sustiva and Gilead’s Truvada is expected. Firms will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products”

You may also be interested in...



Bristol/Gilead HIV Combo Therapy Will Go To FDA By Mid-Year

Bristol-Myers Squibb and Gilead plan to submit an NDA in the second quarter for a fixed-dose combination of Bristol’s Sustiva (efavirenz) and Gilead’s Truvada (emtricitabine/tenofovir disoproxil).

Gilead’s Truvada Trumps Combivir In Rx Market Share For Therapy Class

Gilead Sciences' combination antiretroviral therapy Truvada (emtricitabine/tenofovir) achieved a market-leading 18.7% of total prescriptions in the nucleoside reverse transcriptase inhibitor class during the third quarter, according to Gilead

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel